Guardant Health (NASDAQ:GH) Insider Chris Freeman Sells 63,605 Shares

Guardant Health, Inc. (NASDAQ:GH) insider Chris Freeman sold 63,605 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $169.58, for a total value of $10,786,135.90. Following the sale, the insider directly owned 65,374 shares in the company, valued at $11,086,122.92. The trade was a 49.31% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Chris Freeman also recently made the following trade(s):

• On Friday, May 22nd, Chris Freeman sold 24,406 shares of Guardant Health stock. The shares were sold at an average price of $118.67, for a total value of $2,896,260.02.

Guardant Health Price Performance

Shares of Guardant Health stock opened at $165.09 on Wednesday. Guardant Health, Inc. has a 1 year low of $53.40 and a 1 year high of $176.58. The business has a 50-day moving average of $148.48 and a two-hundred day moving average of $115.94. The company has a market capitalization of $22.15 billion, a P/E ratio of -47.30 and a beta of 1.60.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. BTIG Research increased their target price on Guardant Health from $190.00 to $195.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. Evercore reaffirmed an “outperform” rating and issued a $200.00 price target on shares of Guardant Health in a research note on Monday, July 6th. The Goldman Sachs Group reiterated a “buy” rating and issued a $210.00 price target on shares of Guardant Health in a report on Friday, July 31st. Mizuho raised their price objective on shares of Guardant Health from $175.00 to $200.00 and gave the stock an “outperform” rating in a report on Friday, July 31st. Finally, UBS Group set a $150.00 price objective on shares of Guardant Health in a research report on Wednesday, June 24th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $183.78.

Hedge Funds Weigh In On Guardant Health

Several hedge funds have recently made changes to their positions in GH. Alyeska Investment Group L.P. acquired a new stake in shares of Guardant Health in the 3rd quarter valued at approximately $114,421,000. Price T Rowe Associates Inc. MD increased its holdings in Guardant Health by 33.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,636,078 shares of the company’s stock worth $575,670,000 after buying an additional 1,414,441 shares during the last quarter. Norges Bank bought a new stake in Guardant Health during the fourth quarter worth $128,499,000. Summit Partners Public Asset Management LLC raised its position in Guardant Health by 674.5% during the fourth quarter. Summit Partners Public Asset Management LLC now owns 851,958 shares of the company’s stock worth $87,019,000 after acquiring an additional 741,958 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its stake in Guardant Health by 89.6% in the first quarter. The Manufacturers Life Insurance Company now owns 1,205,701 shares of the company’s stock valued at $111,371,000 after acquiring an additional 569,766 shares during the last quarter. 92.60% of the stock is owned by institutional investors.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.